Bone Health Composition Modulating Osteoblast and Osteoclast Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis often have serious side effects and do not effectively address the underlying biochemical processes leading to bone degradation and inflammation, resulting in significant morbidity and economic burden.
Innovation Solution
Compositions comprising a combination of natural agents that modulate key biochemical processes, including osteoblast formation, osteoclast inhibition, and reduction of inflammatory mediators, to promote bone formation and reduce bone resorption, using phytonutrients, vitamins, and minerals that activate osteogenic pathways and inhibit oxidative stress and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for osteoporosis and related disorders are used, then bone degradation and inflammation are suppressed, but serious side effects occur
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using natural compounds (phytonutrients, vitamins, minerals) instead of synthetic pharmaceuticals. This parameter change maintains therapeutic effectiveness while eliminating serious side effects associated with conventional drugs like bisphosphonates and corticosteroids.
Solution Approach 2:
The composition targets specific biochemical pathways locally affected by osteoporosis and inflammation. It modulates osteoblast formation, osteoclast activity, and inflammatory mediator production at the cellular level, providing localized therapeutic action without systemic side effects.
2Ease of operation
If current treatments address symptoms, then morbidity is reduced, but underlying biochemical processes leading to bone degradation are not effectively addressed
Solution Approach 1:
The composition takes preliminary action by addressing the root biochemical causes of bone degradation before they progress to severe symptoms. It modulates osteoblast and osteoclast activity early in the disease process, preventing bone loss rather than merely treating established osteoporosis.
Solution Approach 2:
The natural compounds in the composition act as intermediaries that modulate the biochemical pathways between nutritional intake and bone metabolism. They facilitate the conversion of dietary components into therapeutic effects on osteoblasts and osteoclasts, addressing underlying mechanisms while managing symptoms.
3Loss of substance
If conventional pharmaceutical treatments are used, then bone resorption is inhibited, but the treatment does not stimulate bone formation
Solution Approach 1:
The composition merges two therapeutic functions into a single formulation: inhibition of bone resorption through osteoclast modulation and stimulation of bone formation through osteoblast activation. This dual-action approach addresses both aspects of bone metabolism simultaneously, unlike conventional single-mechanism treatments.
Solution Approach 2:
The natural compounds in the composition exhibit multi-functionality, acting on multiple targets in the bone metabolism pathway. They simultaneously influence osteoblast differentiation, osteoclast activity, and inflammatory processes, providing comprehensive treatment that both prevents bone loss and promotes bone formation.
Data Source
AI summary
The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and/or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts. The inventive compositions used for administration to human and other mammalian subjects having or at risk for development of osteoporosis comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent that activates expression and/or activity of one or more of the osteogenic transcription factors (Runx2/Cbfα1, Dlx5, Osterix, Msx2); (3) at least one agent that activates expression and/or activity of one or more of bone morphogenetic proteins (BMPs: BMP 2 and 4), alkaline phosphatase (ALP), and osteocalcin; (4) at least one agent capable of activating Wnt/β-catenin signaling pathway; (5) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (6) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); and (7) at least one agent that induces the expression of and/or activates one or more of adenosine monophosphate-activated protein kinase (AMPK), sirtuin (SIRT1) and adiponectin (AP).